Product Description
Flucytosine is a medication used in the management and treatment of systemic and severe candida and cryptococcus infections. It is in the antimetabolite, antifungal class of drugs. Flucytosine (5-FC) action takes effect when it comes in contact with the fungus and is taken up by an enzyme known as cytosine permease. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK557607/)
Mechanisms of Action: Protein Synthesis Inhibitor,TS Inhibitor,DNA Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Brazil | China | Colombia | Czech | Dominican Republic | France | Germany | Greece | India | Ireland | Italy | Malta | Mexico | Morocco | Netherlands | New Zealand | Poland | Russia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: FORTE
Company Location: TORRANCE CA 90502
Company CEO: Dr. Paul Wagner
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, Thailand, United States, Vietnam
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Cryptococcosis|HIV Infections|Histoplasmosis|Meningitis, Cryptococcal|Meningitis, Fungal|Meningitis, Viral
Phase 2: Astrocytoma|Glioblastoma|Glioma|Intestinal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| R21CA282543 | P2 |
Recruiting |
Astrocytoma|Glioma|Glioblastoma |
2034-05-01 |
|
| LAmB-FAST | P3 |
Not yet recruiting |
Histoplasmosis|Cryptococcosis|Meningitis, Cryptococcal|Meningitis, Viral|HIV Infections|Meningitis, Fungal |
2030-01-06 |
|
| TG6002.02 | P2 |
Active, not recruiting |
Intestinal Cancer |
2021-03-12 |